Skip to main content
Clinical Trials/NCT05068934
NCT05068934
Completed
Not Applicable

The Relationship Between Epicardial Fat Tissue and Cardiac Function in HFpEF

Dongying Zhang1 site in 1 country1,083 target enrollmentOctober 12, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure With Preserved Ejection Fraction
Sponsor
Dongying Zhang
Enrollment
1083
Locations
1
Primary Endpoint
Epicardial Fat Tissue
Status
Completed
Last Updated
3 months ago

Overview

Brief Summary

Heart failure with preserved ejection fraction (HFpEF) refers to a group of symptoms and signs of heart failure, normal or near-normal left ventricular systolic function (EF>50%), and ventricular muscle diastolic dysfunction and A clinical syndrome characterized by decreased compliance and increased stiffness. The pathogenesis of HFpEF is related to impaired lipid metabolism and inflammation. Epicardial adipose tissue (Epicardial Adipose tissue, EAT) is a kind of visceral adipose tissue. Related studies have shown that extracardiac Membrane fat is related to inflammation markers, cardiometabolic risk and cardiovascular disease.However, there is still no research investigating the the relationship between epicardial fat thickness and Cardiac Function in HFpEF patients.

Detailed Description

Heart failure with preserved ejection fraction (HFpEF) refers to a group of symptoms and signs of heart failure, normal or near-normal left ventricular systolic function (EF\>50%), and ventricular muscle diastolic dysfunction and A clinical syndrome characterized by decreased compliance and increased stiffness. The pathogenesis of HFpEF is related to impaired lipid metabolism and inflammation. Epicardial adipose tissue (Epicardial Adipose tissue, EAT) is a kind of visceral adipose tissue, which is composed of adipose tissue deposited between the myocardium and the visceral layer of the pericardium. It is closely adjacent to the coronary arteries and myocardium. Related studies have shown that extracardiac Membrane fat is related to inflammation markers, cardiometabolic risk and cardiovascular disease.However, there is still no research investigating the the relationship between epicardial fat thickness and Cardiac Function in HFpEF patients. This study intends to observe the relationship between epicardial fat thickness and left and right functions in patients with HFpEF, and evaluate whether epicardial fat thickness can be used as an indicator of left and right dysfunction.

Registry
clinicaltrials.gov
Start Date
October 12, 2020
End Date
December 15, 2025
Last Updated
3 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Dongying Zhang
Responsible Party
Sponsor Investigator
Principal Investigator

Dongying Zhang

Dongying Zhang

Chongqing Medical University

Eligibility Criteria

Inclusion Criteria

  • Adult aged \>=18years old;
  • Diagnosed with HFpEF.
  • Diagnostic criteria including:
  • left ventricular ejection fraction ≥50%;
  • with the symptoms and/or signs of heart failure;
  • BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL;
  • at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction

Exclusion Criteria

  • LVEF less than 45% at any time;
  • Severe liver failure;
  • Primary pulmonary hypertension;
  • Age \<18 years old.

Outcomes

Primary Outcomes

Epicardial Fat Tissue

Time Frame: On admission

Epicardial Fat Tissue by cardiac color Doppler ultrasound

Cardiac Function

Time Frame: On admission

Left ventricular diastolic function and right ventricular systolic function by cardiac color Doppler ultrasound

Composite Endpoint of Worsening Heart Failure Event and Cardiovascular Death

Time Frame: From date of discharge until the date of first worsening HF event or date of death, whichever came first, assessed up to 5 years

Composite Endpoint of Worsening Heart Failure Event and Cardiovascular Death

Secondary Outcomes

  • Worsening HF Event(From date of discharge until the date of first worsening HF event or date of death, whichever came first, assessed up to 5 years)
  • CV Death(From date of discharge until the date of death, whichever came first, assessed up to 10 years)
  • All-cause Death(From date of discharge until the date of death, whichever came first, assessed up to 10 years)

Study Sites (1)

Loading locations...

Similar Trials